文献速递类风湿关节炎

药理学NAD+增强作为类风湿关节炎有前景治疗方法的临床前特征研究

Preclinical Characterization of Pharmacologic NAD+ Boosting as a Promising Therapeutic Approach in Rheumatoid Arthritis.
PubMed 文献 · Arthritis Rheumatol · 2023-07-28

研究分析253名参与者的NAD+代谢,发现类风湿关节炎患者NAD+水平降低且与炎症和疾病活动度相关,抗TNF治疗可逆转NAD+水平变化;体外实验显示烟酰胺核糖和烟酰胺可提高NAD+水平并改善白细胞促氧化、促凋亡和促炎状态。

要点

  • 类风湿关节炎患者NAD+水平降低,与炎症特征和疾病活动度相关。
  • 抗TNF治疗可调节NAD+水平,且与临床应答平行。
  • 烟酰胺核糖和烟酰胺在体外提高NAD+水平并改善白细胞状态。

核心结论

  • 类风湿关节炎患者NAD+代谢改变,直接与炎症和疾病活动状态相关,抗TNF治疗可逆转该改变。
  • NAD+增强剂在类风湿关节炎患者白细胞中显示的临床前有益效应及其已证实的临床安全性,可能为开展临床试验铺平道路。

研究设计与样本

  • 研究纳入253名参与者;第一队列包括153例类风湿关节炎患者和56名健康供者,评估NAD+水平及NAD+相关基因通路,并用邻近延伸分析检测92种炎症分子。
  • 第二队列包括44例开始抗肿瘤坏死因子(anti-TNF)药物的类风湿关节炎患者,评估3个月后NAD+水平变化及其与临床应答的关联。
  • 机制研究在类风湿关节炎患者外周血单个核细胞(PBMCs)上离体进行,测试烟酰胺和烟酰胺核糖等NAD+增强剂的有益效应。

主要发现

  • 类风湿关节炎样本中NAD+水平降低,与NAD+消耗(sirtuins、聚[ADP-核糖]聚合酶、CD38)、转运(连接蛋白43)和生物合成(NAMPT、NMNATs)相关基因活性和表达改变一致。
  • 无监督聚类分析识别出一组类风湿关节炎患者,具有最高炎症特征、最低NAD+水平和最高疾病活动度(以28关节疾病活动度评分显示)。
  • NAD+水平受抗TNF治疗调节,且与临床应答平行。
  • 使用类风湿关节炎患者PBMCs的体外研究显示,烟酰胺核糖和烟酰胺通过NAMPT和NMNAT提高NAD+水平,并降低其促氧化、促凋亡和促炎状态。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We analyzed NAD+ metabolism in patients with rheumatoid arthritis (RA), its association with disease activity and clinical outcomes of RA, and the therapeutic potential of pharmacologic NAD+ boosting. METHODS: Our study included 253 participants. In the first cohort, comprising 153 RA patients and 56 healthy donors, we assessed NAD+ levels and NAD+ -related gene pathways. We analyzed 92 inflammatory molecules by proximity extension assay. In the second cohort, comprising 44 RA patients starting anti-tumor necrosis factor (anti-TNF) drugs, we evaluated changes in NAD+ levels and their association with clinical response after 3 months. Mechanistic studies were performed ex vivo on peripheral blood mononuclear cells (PBMCs) from patients with RA to test the beneficial effects of NAD+ boosters, such as nicotinamide and nicotinamide riboside. RESULTS: Reduced NAD+ levels were found in RA samples, in line with altered activity and expression of genes involved in NAD+ consumption (sirtuins, poly[ADP-ribose] polymerase, CD38), transport (connexin 43), and biosynthesis (NAMPT, NMNATs). Unsupervised clustering analysis identified a group of RA patients with the highest inflammatory profile, the lowest NAD+ levels, and the highest disease activity (as shown by the Disease Activity Score in 28 joints). NAD+ levels were modulated by anti-TNF therapy in parallel with the clinical response. In vitro studies using PBMCs from RA patients showed that nicotinamide riboside and nicotinamide increased NAD+ levels via NAMPT and NMNAT and reduced their prooxidative, proapoptotic, and proinflammatory status. CONCLUSION: RA patients display altered NAD+ metabolism, directly linked to their inflammatory and disease activity status, which was reverted by anti-TNF therapy. The preclinical beneficial effects of NAD+ boosters, as shown in leukocytes from RA patients, along with their proven clinical safety, might pave the way for the development of clinical trials using these compounds.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Perez-Sanchez C, Escudero-Contreras A, Cerdó T, et al. Preclinical Characterization of Pharmacologic NAD+ Boosting as a Promising Therapeutic Approach in Rheumatoid Arthritis. Arthritis Rheumatol. 2023. PMID: 37094367. doi:10.1002/art.42528

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。